132 related articles for article (PubMed ID: 15779420)
1. [Effects of mitiglinide in treatment of impaired glucose tolerance].
Katahira H; Ishida H
Nihon Rinsho; 2005 Feb; 63 Suppl 2():444-50. PubMed ID: 15779420
[No Abstract] [Full Text] [Related]
2. [Nateglinide and mitiglinide].
Odawara M
Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
[TBL] [Abstract][Full Text] [Related]
3. [A rapid- and short-acting insulinotropic agent KAD-1229].
Komatsu H; Ohnota H; Koizumi T; Satoh F
Nihon Rinsho; 1997 Nov; 55 Suppl():171-9. PubMed ID: 9434463
[No Abstract] [Full Text] [Related]
4. [Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset].
Ojima K; Kiyono Y; Kojima M
Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):245-55. PubMed ID: 15467258
[TBL] [Abstract][Full Text] [Related]
5. [Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia].
Hirose T
Nihon Rinsho; 2005 Dec; 63(12):2237-44. PubMed ID: 16363700
[TBL] [Abstract][Full Text] [Related]
6. [Mitiglinide (KAD-1229)].
Kusama H; Shibata N
Nihon Rinsho; 2002 Sep; 60 Suppl 9():559-65. PubMed ID: 12387051
[No Abstract] [Full Text] [Related]
7. Mitiglinide. KAD 1229.
Drugs R D; 1999 Aug; 2(2):114-5. PubMed ID: 10820654
[No Abstract] [Full Text] [Related]
8. [Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Nakamura J
Nihon Rinsho; 2005 Feb; 63 Suppl 2():457-61. PubMed ID: 15779422
[No Abstract] [Full Text] [Related]
9. [Glinide(s), sulfonylurea(s)].
Arakawa M; Hirose T
Nihon Rinsho; 2006 Nov; 64(11):2107-12. PubMed ID: 17087304
[TBL] [Abstract][Full Text] [Related]
10. [Effects of nateglinide in impaired glucose tolerance subjects].
Hirose T
Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
[No Abstract] [Full Text] [Related]
11. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
12. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.
Ono Y; Kameda H; Cho KY
Expert Opin Pharmacother; 2013 Mar; 14(4):361-70. PubMed ID: 23414242
[TBL] [Abstract][Full Text] [Related]
13. [Structures and mechanisms for non SU insulin secretagogues].
Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():362-70. PubMed ID: 12387019
[No Abstract] [Full Text] [Related]
14. Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients.
Malaisse WJ
Expert Opin Pharmacother; 2008 Oct; 9(15):2691-8. PubMed ID: 18803455
[TBL] [Abstract][Full Text] [Related]
15. ATP-sensitive K+ channels and insulin secretion: their role in health and disease.
Ashcroft FM; Gribble FM
Diabetologia; 1999 Aug; 42(8):903-19. PubMed ID: 10491749
[No Abstract] [Full Text] [Related]
16. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide.
Ohnota H; Koizumi T; Tsutsumi N; Kobayashi M; Inoue S; Sato F
J Pharmacol Exp Ther; 1994 May; 269(2):489-95. PubMed ID: 8182516
[TBL] [Abstract][Full Text] [Related]
17. Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study.
Ando K; Nishimura R; Seo C; Tsujino D; Sakamoto M; Utsunomiya K
Expert Opin Pharmacother; 2014 Dec; 15(17):2479-85. PubMed ID: 25327311
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of sulphonylureas: role of K(ATP) channels.
Howes LG
Diabetes Obes Metab; 2000 Apr; 2(2):67-73. PubMed ID: 11220526
[No Abstract] [Full Text] [Related]
19. Mitiglinide: KAD 1229, S 21403.
Drugs R D; 2004; 5(2):98-101. PubMed ID: 15293870
[TBL] [Abstract][Full Text] [Related]
20. Effects of combination of mitiglinide with various oral antidiabetic drugs in streptozotocin-nicotinamide-induced type 2 diabetic rats and Zucker fatty rats.
Akahane K; Ojima K; Yokoyama A; Inoue T; Kiguchi S; Tatemichi S; Takeda H; Imai Y
Clin Exp Pharmacol Physiol; 2017 Dec; 44(12):1263-1271. PubMed ID: 28744906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
